spot_img

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company.  We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."

Parkinson’s Foundation Invests $3.4 Million in Research Grants

Summation

  • Parkinson’s Foundation research grants fund a diverse array of research studies that provide pre and postdoctoral researchers with training opportunities and established scientists and clinicians with the support to test innovative ideas that can lead to impactful research findings in the Parkinson’s field.
  • Grants support Parkinson’s research across a variety of disciplines for scientists who are actively studying various aspects of Parkinson’s with the hope of making life better for people with the disease and ultimately, leading to a cure.
  • “With the support of the Parkinson’s Foundation, we hope to better understand how the nervous system functions as it relates to people with advanced Parkinson’s disease experience freezing gait, an inability to move their feet, during demanding or particularly stressful situations,”.

The Parkinson’s Foundation today announced a $3.4 million investment across 34 research grants to advance promising Parkinson’s disease (PD) research. Grants support Parkinson’s research across a variety of disciplines for scientists who are actively studying various aspects of Parkinson’s with the hope of making life better for people with the disease and ultimately, leading to a cure.

“The Parkinson’s Foundation continues to provide these annual grant opportunities especially during the COVID-19 pandemic to ensure that PD research can successfully move forward,” said John L. Lehr, President and Chief Executive Officer of the Parkinson’s Foundation. “These research grants are critical to driving better patient outcomes and ensuring a better future for people with Parkinson’s disease.”

Parkinson’s Foundation research grants fund a diverse array of research studies that provide pre and postdoctoral researchers with training opportunities and established scientists and clinicians with the support to test innovative ideas that can lead to impactful research findings in the Parkinson’s field.

“With the support of the Parkinson’s Foundation, we hope to better understand how the nervous system functions as it relates to people with advanced Parkinson’s disease experience freezing gait, an inability to move their feet, during demanding or particularly stressful situations,” said Kevin Wilkins, Ph.D., a postdoctoral grant recipient. “We hope to develop ways to identify those at risk of developing cognitive and walking impairments as their disease progresses and provide the key to better therapies.”

This year the Foundation invested $450,000 in Impact Award programs. This award supports high-risk, high-reward projects that discover more about the biology of Parkinson’s and new treatments to people with Parkinson’s. Impact Award recipients received a maximum of $150,000 for approximately one year.

“These research grants allow us to better understand Parkinson’s disease and move the needle forward for better care and therapies for people with PD,” said James Beck, PhD, Chief Scientific Officer of the Parkinson’s Foundation. “We are thrilled to support these highly-promising grant recipients as they advance research towards a cure.”

Parkinson’s Foundation research investments are selected through a competitive application process and peer-reviewed by a panel that includes scientific experts and Foundation-trained research advocates. Since 1957, the Foundation has invested more than $365 million in Parkinson’s research and clinical care.

Research award categories include independent investigator awards, fellowships and early career awards, collaborative fellowships awards and Parkinson’s Foundation Research Centers awards. For more information about Parkinson’s Foundation research grants, visit here.

Stryker Reports: 1st European Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

The Gamma4 Hip Fracture Nailing System is designed to treat hip and femur fractures. Its nail design is informed by Stryker's SOMA database, which includes over 37,000 3D bone models generated from CT scans. The system received CE certification in November 2023 and has been utilized in over 25,000 cases in North America and Japan.

Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM

The Tandem Mobi Insulin pump is small enough to be worn almost anywhere, including a coin pocket, providing users with more discretion, comfort, and options for how they manage their diabetes. Powered by Control-IQ technology, which has demonstrated in real-world studies improved time in range overnight and during the day4, Tandem Mobi connects with Dexcom G7 or Dexcom G6 to predict glucose levels 30 minutes in advance and automatically adjusts insulin, if needed, to help prevent highs and lows.

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Ted Raad, Chief Executive Officer of Pulmatrix, commented, "MannKind's interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind's Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy